

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Antengene Corporation Limited

德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6996)

VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE

This announcement is made by Antengene Corporation Limited (the “**Company**”) on a voluntary basis to provide its shareholders and potential investors with information in relation to the latest developments of the Company.

The board of directors of the Company (the “**Board**”) wishes to announce that it has an intention to exercise its powers under the general mandate (the “**Share Repurchase Mandate**”) given to the Board pursuant to the resolutions of the shareholders of the Company (the “**Shareholders**”) passed at the annual general meeting of the Company (the “**AGM**”) held on June 18, 2021, to repurchase up to 67,118,064 shares of the Company (the “**Shares**”), being 10% of the total number of the issued Shares as at the date of the AGM (the “**Proposed Share Repurchase**”), with such mandate to expire upon whichever is the earliest of: (a) the conclusion of the next annual general meeting of the Company; (b) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any applicable law of the Cayman Islands to be held; or (c) the date on which the authority set out in the ordinary resolution approving the Share Repurchase Mandate is revoked or varied by an ordinary resolution of the Shareholders in general meeting.

On October 2, 2021, the Board has decided to utilize the Share Repurchase Mandate and, subject to market conditions, repurchase Shares in the open market from time to time to use up to HK\$100 million in funds for the Proposed Share Repurchase. The Company will conduct the Proposed Share Repurchase in compliance with the articles of association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Codes on Takeovers and Mergers and Share Buy-backs, the Companies Law of the Cayman Islands and all applicable laws and regulations to which the Company is subject to.

The Company will finance the Proposed Share Repurchase by its internal resources.

The Board believes that a share repurchase in the present conditions will demonstrate the Company’s confidence in its own business outlook and prospects and would, ultimately, benefit the Company and create value to the Shareholders. The Board believes that the current financial resources of the Company would enable it to implement the Proposed Share Repurchase while maintaining a solid financial position. The Board considers that the Proposed Share Repurchase is in the best interest of the Company and its Shareholders as a whole. For further details of the Proposed Share Repurchase, please refer to the attached press release of the Company.

Shareholders and potential investors should note that any repurchase may be done subject to market conditions and at the Board's absolute discretion. There is no assurance of the timing, quantity or price of any repurchase. Shareholders and potential investors should therefore exercise caution when dealing in the Shares.

By Order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, October 4, 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Jay Mei, Mr. John F. Chin, Mr. Donald A. Lung and Dr. Kevin P. Lynch as executive directors; Dr. Kan Chen and Mr. Yanling Cao as non-executive directors; and Mr. Mark J. Alles, Ms. Jing Qian and Mr. Sheng Tang as independent non-executive directors.

Antengene Announces Up to HK\$100 million Share Repurchase Program

Shanghai and Hong Kong, PRC, October 4, 2021 – Antengene Corporation Limited (“**Antengene**” or the “**Company**”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that its board of directors resolved to repurchase shares worth up to HK\$100 million in the open market from time to time.

At the Annual General Meeting of the Company held on June 18, 2021, a general mandate of potential repurchasing up to 10% of the total issued shares of the Company has been given to the board by the shareholders. On October 2, 2021, the board formally resolved to utilize the mandate to repurchase up to HK\$100 million of its ordinary shares.

The Company will finance the share repurchase with its existing available cash reserves.

The board believes that a share repurchase in the present conditions will demonstrate the Company’s confidence in its own business outlook and prospects and would, ultimately, benefit the Company and create value to its shareholders. The board also believes that the current strong financial resources of the Company would enable it to implement the share repurchase while maintaining a solid financial position.

The Company will conduct the share repurchase in compliance with the share repurchase mandate, the memorandum and articles of association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Codes on Takeovers and Mergers and Share Buybacks, the Companies Law of the Cayman Islands and all applicable laws and regulations to which the Company is subject.

“Antengene is at an inflection point of becoming a revenue generating company across the Asia Pacific with our first de-risked commercial stage asset. More importantly, we believe our pipeline of highly differentiated assets focused to solve unmet medical needs of some of the most challenging conditions for cancer worldwide are going to deliver value in the near future. We believe this share repurchase program is a strong indication of our confidence in the underlying prospects of our unique pipeline, strong ability in execution, as well as our long-term outlook for the Company,” said Dr Jay Mei, Founder, Chairman and Chief Executive Officer of Antengene. “We are committed to maintaining a disciplined approach to capital allocation, and we believe that our strong financial position allows us to deliver value to our shareholders, while continuing to execute our business strategy for the long term growth of Antengene.”

About Antengene

Antengene Corporation Limited (“**Antengene**”, SEHK: 6996.HK) is a leading clinical-stage R&D driven biopharmaceutical company focused on innovative medicines for oncology and other life-threatening diseases. Antengene aims to provide the most advanced anti-cancer drugs to patients in the Asia Pacific Region and around the world. Since the beginning of operations in 2017, Antengene has built a broad and expanding pipeline of clinical and pre-clinical stage assets through partnerships as well as in-house drug discovery and obtained 16 investigational new drug (IND) approvals and submitted 6 new drug applications (NDA) in multiple markets in Asia Pacific, with the NDA for selinexor in South Korea already approved through a priority review process. Antengene’s vision is to “Treat Patients Beyond Borders”. Antengene is focused on and committed to addressing significant unmet medical needs by discovering, developing and commercializing first-in-class/best-in-class therapeutics.